Girentuximab Biosimilar - Research Grade

Human

Carbonic Anhydrase IX

>1mg/ml

Human IgG1

https://www.imgt.org/mAb-DB/

ICH3002

Q16790

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of girentuximab, supplied strictly for research use only. It reproduces the antigen-binding specificity of the originator antibody against Carbonic Anhydrase IX (CA IX / CA9), a fully human IgG1 built around this target, without being formulated or intended as the clinical drug. It is provided in bulk milligram-to-gram quantities and at low-endotoxin research grade (<1 EU/mg standard; <0.5 EU/mg ultra-low), making it well suited to demanding assay formats and preclinical experimental workflows. Typical research applications include use as a positive or isotype-matched binding reference, a tool for probing CA IX expression on tumour-derived and hypoxia-induced cell models, a benchmarking reagent when characterising novel anti-CA IX binders, and a starting scaffold for ADCC or antibody-drug-conjugate (ADC) development studies. Because it is an off-clinical analog rather than the therapeutic product, it enables reproducible bench-scale comparison and method development while removing the cost and access constraints of clinical-grade material. Not for human or veterinary use. Carbonic Anhydrase IX (CA IX, gene CA9; UniProt Q16790) is a transmembrane, zinc-dependent metalloenzyme that catalyses the reversible hydration of carbon dioxide to bicarbonate and protons, contributing to pH regulation in the tumour microenvironment. It is a member of the alpha-carbonic anhydrase family, distinguished by an N-terminal proteoglycan-like domain, a catalytic extracellular domain, a single transmembrane segment, and a short intracellular tail. CA IX expression is tightly driven by hypoxia through the HIF-1 pathway and is characteristically upregulated in clear-cell renal cell carcinoma, largely as a consequence of VHL loss, as well as in other solid tumours. By exporting protons and supporting intracellular alkalinisation with extracellular acidification, CA IX promotes tumour cell survival, migration, and adaptation to low oxygen, making it a widely studied hypoxia and tumour-associated marker.

CAIX, CA-IX

Detects human Carbonic Anhydrase IX. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Girentuximab Biosimilar - Research Grade.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Girentuximab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Girentuximab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Girentuximab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Girentuximab that binds human Carbonic Anhydrase IX.